Efficacy and safety of anlotinib hydrochloride combined with nivolumab in the treatment of advanced upper gastrointestinal tumor as second-line or later-line therapy: The results of gastric cancer cohort

被引：0
|
作者：
Cui, Yuehong
Yu, Yiyi
Wu, Jing
Li, Qian
Liang, Li
Wang, Yan
Yu, Shan
Liu, Tianshu
机构：
[1] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Oncol, Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16015
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of paclitaxel with or without targeted therapy as second-line therapy in advanced gastric cancer A meta-analysis
    Zheng, Ting
    Jin, Jianjiang
    Zhang, Yuefeng
    Zhou, Li
    MEDICINE, 2020, 99 (25) : E20734
  • [22] Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer: a single-center observational study
    Zhang, Yong
    Gou, Miaomiao
    Han, Chun
    Li, Juan
    Wang, Lijie
    Qiao, Qian
    Hu, Yi
    Bai, Li
    Liu, Zhefeng
    ANTI-CANCER DRUGS, 2018, 29 (02) : 184 - 189
  • [23] Efficacy and safety of low-dose apatinib combined with chemotherapy as second-line treatment for advanced gastric cancer: a meta-analysis
    Wang, Liang
    Li, Juyuan
    Chen, Huamin
    CHEMOTHERAPY, 2024, 69 (01) : 11 - 22
  • [24] Efficacy and safety of intermittent versus continuous dosing schedule of apatinib combined with docetaxel as second-line treatment for advanced gastric cancer.
    He, Yifu
    Yan, Ying
    Wang, Gang
    Sun, Yubei
    Xu, Tengyun
    Wu, Shusheng
    Luo, Huiqin
    Ke, Lihong
    Hu, Xiaoxiu
    Niu, Jiayu
    Li, Huimin
    Chen, Wenju
    Xu, Huijun
    Cao, Lulu
    Sun, Yancai
    Liu, Chenxuan
    Ji, Chushu
    Hu, Bing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Efficacy and Safety of Antiangiogenic Therapy plus Immunotherapy as Later-line Treatment for Small Cell Lung Cancer
    Chen, T.
    Jiang, J.
    Wang, M.
    Hu, X.
    Shi, Y.
    Liu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S711 - S711
  • [26] Efficacy and safety of intermittent dosing schedule of apatinib for advanced gastric cancer in second-line setting
    He, Y.
    Yan, Y.
    Wang, G.
    Sun, Y.
    Xu, T.
    Wu, S.
    Niu, J.
    Li, H.
    Xu, H.
    Luo, H.
    Ke, L.
    Chen, W.
    Cao, L.
    Hu, X.
    Ji, C.
    Hu, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 22 - 22
  • [27] Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study
    Ryosuke Kumanishi
    Shigenori Kadowaki
    Seiichiro Mitani
    Tomohiro Matsushima
    Takatsugu Ogata
    Yukiya Narita
    Toshiki Masuishi
    Hideaki Bando
    Masahiro Tajika
    Hisateru Yasui
    Hiroki Hara
    Kei Muro
    International Journal of Clinical Oncology, 2023, 28 : 756 - 763
  • [28] Efficacy and Safety of Capecitabine and Oxaliplatin Combination as Second-Line Treatment in Advanced Colorectal Cancer
    Heras, Panagiotis
    Kritikos, Konstantinos
    Hatzopoulos, Antonios
    Xourafas, Vasihos
    Kritikos, Nikolaos
    Karagiannis, Stefanos
    Mitsibounas, Dimitrios
    AMERICAN JOURNAL OF THERAPEUTICS, 2009, 16 (04) : 319 - 322
  • [29] Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study
    Shimozaki, Keitaro
    Nakayama, Izuma
    Takahari, Daisuke
    Nagashima, Kengo
    Yoshino, Koichiro
    Fukuda, Koshiro
    Fukuoka, Shota
    Osumi, Hiroki
    Ogura, Mariko
    Wakatsuki, Takeru
    Ooki, Akira
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    JOURNAL OF GASTRIC CANCER, 2023, 23 (04) : 609 - 621
  • [30] Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study
    Kumanishi, Ryosuke
    Kadowaki, Shigenori
    Mitani, Seiichiro
    Matsushima, Tomohiro
    Ogata, Takatsugu
    Narita, Yukiya
    Masuishi, Toshiki
    Bando, Hideaki
    Tajika, Masahiro
    Yasui, Hisateru
    Hara, Hiroki
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (06) : 756 - 763
12345